Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.93 - $7.32
Previous CloseN/A
Volume71.38K
Average Volume (3M)2.55M
Market Cap
$318.71M
Enterprise Value$305.72M
Total Cash (Recent Filing)$84.16M
Total Debt (Recent Filing)$23.98M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 18, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding51,156,734
10 Day Avg. Volume1,958,147
30 Day Avg. Volume2,545,656
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.72
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue54.13
Enterprise Value/Gross Profit-183.40
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$20.50Price Target Upside219.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbeona announced the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155M, providing sufficient cash for more than two years of operating expenses.
Product LaunchZEVASKYN is now officially commercially available in the U.S. after the activation of Ann & Robert H. Lurie Children’s Hospital of Chicago as the first of five qualified treatment centers.
Regulatory ApprovalThe FDA approved the Biologics License Application for Abeona's lead candidate, prademagene zamikeracel, signaling confidence in its treatment potential.
Bears Say
Pricing ConcernsThe ZEVASKYN list price is significantly higher than initially forecasted, suggesting a strong revenue potential for Abeona.
Profitability TimelineAbeona anticipates becoming profitable in early 2026, with projections indicating potential profitability before the end of this year depending upon the trajectory of the ZEVASKYN launch.
---
Ownership Overview
6.58% Insiders
4.87% Mutual Funds
44.24% Other Institutional Investors
38.99% Public Companies and Individual Investors
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.93 and its highest was $7.32 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $318.71M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 89 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on May 15, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.118.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 51,156,734 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went up 7.421%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
---
Abeona Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (219.31% Upside)
$20.50 (219.31% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $45.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.59%
12-Months-Change
Fundamentals
Return on Equity
-271.78%
Trailing 12-Months
Asset Growth
32.79%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
---
ABEO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted the successful FDA approval and positive market reception of ZEVASKYN, as well as strategic financial moves to ensure the company's stability. However, delays in patient treatment and increased operating expenses were noted as challenges.Read More>---
ABEO Stock 12 Month Forecast
Average Price Target
$20.50
▲(219.31% Upside)
Technical Analysis
Astria Therapeutics
―
iTeos Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Candel Therapeutics
―
---